Shenzhen New Industries Biomedical (300832) - Total Liabilities
Based on the latest financial reports, Shenzhen New Industries Biomedical (300832) has total liabilities worth CN¥831.98 Million CNY (≈ $121.74 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 300832 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Shenzhen New Industries Biomedical - Total Liabilities Trend (2012–2024)
This chart illustrates how Shenzhen New Industries Biomedical's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Shenzhen New Industries Biomedical (300832) total assets.
Shenzhen New Industries Biomedical Competitors by Total Liabilities
The table below lists competitors of Shenzhen New Industries Biomedical ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hoshine Silicon Ind Co Ltd
SHG:603260
|
China | CN¥51.93 Billion |
|
Sundaram Finance Limited
NSE:SUNDARMFIN
|
India | Rs709.02 Billion |
|
AutoNation Inc
NYSE:AN
|
USA | $12.40 Billion |
|
ChinaLin Securities Co Ltd
SHE:002945
|
China | CN¥29.12 Billion |
|
Birkenstock Holding plc
NYSE:BIRK
|
USA | $2.27 Billion |
|
Ultrapar Participações S.A
F:UGR
|
Germany | €31.62 Billion |
|
Strathcona Resources Ltd.
TO:SCR
|
Canada | CA$4.41 Billion |
|
Corcept Therapeutics Incorporated
NASDAQ:CORT
|
USA | $176.89 Million |
Liability Composition Analysis (2012–2024)
This chart breaks down Shenzhen New Industries Biomedical's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Shenzhen New Industries Biomedical net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.65 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shenzhen New Industries Biomedical's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shenzhen New Industries Biomedical (2012–2024)
The table below shows the annual total liabilities of Shenzhen New Industries Biomedical from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.04 Billion ≈ $152.60 Million |
+53.79% |
| 2023-12-31 | CN¥678.09 Million ≈ $99.23 Million |
+10.25% |
| 2022-12-31 | CN¥615.06 Million ≈ $90.00 Million |
+17.49% |
| 2021-12-31 | CN¥523.51 Million ≈ $76.61 Million |
+4.39% |
| 2020-12-31 | CN¥501.49 Million ≈ $73.38 Million |
+57.24% |
| 2019-12-31 | CN¥318.92 Million ≈ $46.67 Million |
+16.17% |
| 2018-12-31 | CN¥274.52 Million ≈ $40.17 Million |
+9.81% |
| 2017-12-31 | CN¥250.00 Million ≈ $36.58 Million |
+34.59% |
| 2016-12-31 | CN¥185.75 Million ≈ $27.18 Million |
+48.66% |
| 2015-12-31 | CN¥124.94 Million ≈ $18.28 Million |
-7.39% |
| 2014-12-31 | CN¥134.92 Million ≈ $19.74 Million |
-16.78% |
| 2013-12-31 | CN¥162.12 Million ≈ $23.72 Million |
+149.68% |
| 2012-12-31 | CN¥64.93 Million ≈ $9.50 Million |
-- |
About Shenzhen New Industries Biomedical
Shenzhen New Industries Biomedical Engineering Co., Ltd., engages in the research, development, production, and sale of clinical laboratory instruments and in vitro diagnostic reagents to hospitals in China and internationally. It offers immunoassay machine, biochemistry/electrolyte, integrated system, lab automation, molecular diagnostics, hemolumi and rapid test solutions. The company was found… Read more